Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
11 evidence topics · 7 sources
Plasma aldosterone suppression after single and multiple doses in healthy participants
“Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAC (AUC0–24) was reduced by up to 40% with single 100‐ to 200‐mg doses and up to 70% with single 400‐ to 800‐mg doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone rebound after discontinuation in healthy participants
“From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From Day 7 to Day 9, clear reductions in the urinary log10 (10 × Na+/K+) ratio were observed, suggesting a rebound effect for the sodium/potassium ratio as well.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Basal and cosyntropin-stimulated cortisol in healthy participants
“During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma renin activity, 11-deoxycorticosterone, serum potassium, and natriuresis in healthy participants
“Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b). Elevations in serum potassium concentrations due to lorundrostat‐mediated reductions in PAC were mild and seen across all doses tested (Figure 3c). These effects declined during the washout period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone reduction in participants with hypertension: company summary
Serum aldosterone, plasma renin activity, and cortisol in uncontrolled hypertension: Target-HTN
“Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote